About the company

Mass spectrometry

The mass spectrometry technology, whose discoverer was awarded the Nobel Prize in Chemistry in 2002, has revolutionized the field of proteomics and allowed bioinformatics to gain an enormous potential and great focus. Bioinformatics, the data analysis and development of medical software, is today a fundamentally important part of proteomics and metabolomics. Here, Binary Detect appears in the frontline within a niche with enormous needs and great development potential.

The mass spectrometry technology has enabled physicians and researchers to analyze the body’s proteins, peptides, amino acids and metabolites. This offers us, within a not too long future, completely new methods for studying and detecting diseases such as different types of cancer at an early stage, diseases that are difficult to detect at an early stage today and cause many deaths.

Lack of analysis software has become a bottleneck in the development of new drugs or in the search for important proteins, so-called biomarkers, which help diagnose diseases such as, for example, cancer. The future of early disease diagnosis lies in the development of new tools for biomarker detection. Due to the fact that the mass spectrometry technology and computer programs/software (such as Spectrolyzer) have become really powerful, such analytical methods have rapidly begun to spread all around the world.